NanoMed Pharmaceuticals Inc.
This article was originally published in Start Up
Executive SummaryThe idea of delivering drugs encased in lipids was a popular one in the early days of the biotechnology industry but manufacturing problems pushed lipid-based drug delivery from favor. NanoMed Pharmaceuticals thinks it has found a way to get lipids to fulfill their potential as delivery vehicles, shielding the drugs they contain from cellular mechanisms responsible for drug resistance. The start-up aims to leverage its know-how to treat cancers notoriously resistant to chemotherapy.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.